OBJECTIVE: To study the
efficacy and
safety in
patients with decompensative
hepatic cirrhosis treated with
Lamivudine .
METHODS: Eighteen decompensative
hepatic cirrhosis (B) (active
phage )
patients accompanied with hypeersplenism were treated with
Lamivudine 100mg po. per day. The total
course of
treatment was 3 months to 6 months when HBVDNA became negative and
HBeAg seroconversion occurred in these
patients after
Lamivudine treatment . The
efficacy and
safety in
patients were evaluated as follows HBVDNA were negative,
HBeAg seroconversion occurred and
hepatic cirrhosis child -stageing changed. The
efficacy and
safety between treated group and contrast group were compared during
treatment with Lamifudine for 1 year and follow-up foe 1 year after completing
treatment .
RESULTS: The total
efficacy of treated group was 27.7% and 71.43% respectively during the phase II trial and the
safety was good in these
patients .
CONCLUSION: The
efficacy and
safety of
Lamivudine are good while it is used in non-registered adaptation of decompensative
hepatic cirrhosis with
hypersplenism .